
To study the longitudinal effects of glucocorticoids (GCs) and tocilizumab, an IL‐6 receptor inhibitor, on haemoglobin A1c (HbA1c) during GC tapering. In 209 patients, the median HbA1c decreased by 0.50% (p<0.01) in the tocilizumab/GC group and by 0.10% (p<0.01) in the GC‐only group. Tocilizumab treatment was associated with a substantial reduction in HbA1c, independent of GC exposure, which may be achieved through a combination of glycemic and non‐glycemic effects.
Like
Save
Share